LTR Pharma has today announced key results from its pivotal study demonstrating that SPONTAN® Nasal Spray works significantly faster than the oral tablet, achieving 470% faster absorption than oral vardenafil tablets and reaching its peak concentration in 12 min vs 56 min.

SPONTAN also displayed clinically relevant comparable bioavailability, with 111.8% dose-normalised bioavailability relative to the oral tablet, despite the lower 5mg dose. Additionally, SPONTAN delivers 155.6% higher peak concentration despite using only half the dose. 

LTR Pharma Chairman, Lee Rodne said:

“These study results mark a significant milestone for LTR Pharma. SPONTAN’s pharmacokinetic profile and rapid onset of action demonstrate its potential to disrupt the global ED market. We are now well-positioned to accelerate our commercialisation strategy, including advancing regulatory discussions and exploring strategic partnerships. This success reinforces our commitment to delivering innovative solutions that can significantly improve patients’ lives while creating value for our shareholders.”

Click here to read the ASX release.